Is cholesterol a risk factor for stroke?: Yes

Archives of Neurology

Volumn 56, Issue 12, 1999, Pages 1518-1520

  Demchuk, Andrew M ^a   Hess, David C ^b   Brass, Lawrence M ^c   Yatsu, Frank M ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; CHOLESTEROL; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; STATIN; TRIACYLGLYCEROL;

ARTICLE; ATHEROSCLEROSIS; BRAIN HEMORRHAGE; BRAIN INFARCTION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; PRIORITY JOURNAL; RISK FACTOR; STROKE;

EID: 0032732480     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.56.12.1518     Document Type: Article

References (36)

1. Yatsu FM, Villar-Cordova C. Atherosclerosis. In: Barnett HJM, Mohr JP, Stein BM, Yatsu FM, eds. Stroke Pathophysiology, Diagnosis, and Management. 3rd ed. Philadelphia, Pa: Churchill Livingstone; 1998:29-40.
2. Khaw K-T. Epidemiology of stroke. J Neurol Neurosurg Psychiatry. 1996;61:333-338.
3. Yatsu FM. Dietary cholesterol: does it aggravate strokes due to atherosclerosis? Neurology. 1981; 31:1535-1536.
4. Qizilbash N. Are risk factors for stroke and coronary disease the same? Curr Opin Lipidol. 1998; 9:325-328.
5. Kannel WB, Dawber TR, Cohen ME, McNamara PM. Vascular disease of the brain - epidemiologic aspects: the Framingham Study. Am J Public Health. 1965;55:1355-1366.
6. Kagan A, Popper JS, Rhoads GG. Factors related to stroke incidence in Hawaiian Japanese men, the Honolulu Heart Study. Stroke. 1980;11:14-21.
7. Iso H, Jacobs DR, Wentworth D, Neaton JD, Cohen JD, for the MRFIT Research Group. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the Multiple Risk Factor Intervention Trial. N Engl J Med. 1989;320:904-910.
8. Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Blood pressure, cholesterol, and stroke in eastern Asia. Lancet. 1998; 352:1801-1807.
9. Joubert J, Lemmer LB, Fourie PA. van Gelder AL, Darazs B. Are clinical differences between black and white stroke patients caused by variations in the atherosclerotic involvement of the arterial tree? S Afr Med J. 1990;77:248-251.
10. Tell GS, Crouse JR, Furberg CD. Relation between lipids, lipoprotein, and cerebrovascular atherosclerosis: a review. Stroke. 1988;19:423-430.
11. Hachinski V, Graffagnino C, Beaudry M, et al. Lipids and stroke: a paradox resolved. Arch Neurol. 1996;53:303-308.
12. Yasaka M, Yamaguchi T, Shichiri M. Distribution of atherosclerosis and risk factors in atherothrombotic occlusion. Stroke. 1993;24:206-211.
13. Kasturi R, Yatsu FM, Alam R, Rogers S. Restriction fragment length polymorphism of the apoprotein A-I-C-III gene cluster in control and stroke-prone white and black subjects: racial differences. Stroke. 1992;23:1257-1264.
14. Wiseman SA, Powell JT, Barber N, Humphries SE, Greenhalgh RM. Influence of apolipoproteins on the anatomical distribution of arterial disease. Atherosclerosis. 1991;89:231-237.
15. Yatsu FM, Kasturi R, Alam R, Kraus J, Rogers S, DeGraba T. Molecular biology of atherothrombotic brain infarction. Stroke. 1990;21(suppl 11):131-133.
16. Alam R, Yatsu FM, Kasturi R, Bui G. Low and high density lipoprotein metabolism in atherothrombotic brain infarction. Stroke. 1992;23:1265-1270.
17. Grotta JC, Yatsu FM, Pettigrew LC, et al. Prediction of carotid stenosis progression by lipid and hematologic measurements. Neurology. 1989; 39:1325-1331.
18. Castaigne A, Haziza F, Lopes-Darmon ME. Heart and brain: are the risk factors the same? are the results of primary and secondary trials comparable? Arch Mal Coeur Vaiss. 1998;91:59-63.
19. Benfante R, Yano K, Hwang L-J, Curb JD, Kagan A, Ross W. Elevated serum cholesterol is a risk factor for both coronary heart disease and thromboembolic stroke in Hawaiian Japanese men: implications of shared risk. Stroke. 1994;25:814-820.
20. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1995;345:1274-1275.
21. Sacks FM, Pfeffer MA, Moye LA, et al, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
22. Plehn JF, Davis BR, Sacks FM, et al, for the CARE Investigators. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) Study. Circulation. 1999;99:216-223.
23. The West of Scotland Coronary Prevention Study Group. A coronary primary prevention study of Scottish men aged 45-64 years: trial design. J Clin Epidemiol. 1992;45:849-860.
24. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
25. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. JAMA. 1997;278:313-321.
26. Blauw GJ, Lagaay AM, Smelt AHM, Westendorp RGJ. Stroke, statins, and cholesterol: a meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke. 1997;28:946-950.
27. Bucher HC, Griffith LE, Guyatt GH. Effect of HMG-coA reductase inhibitors on stroke: a meta-analysis of randomized, controlled trials. Ann Intern Med. 1998;128:89-95.
28. MacMahon S, Sharpe N, Gamble G, et al. Effects of lowering average or below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID Atherosclerosis Sub-study: LIPID Trial Research Group. Circulation. 1998;97:1784-1790.
29. Hodis HN, Mack WJ, LaBree L, et al. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: a randomized, controlled clinical trial. Ann Intern Med. 1996;124:548-556.
30. Mercuri M, Bond MG, Sirtori CR, et al. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. Am J Med. 1996;101:627-634.
31. Hulley S, Grady D, Bush T, et al, for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogens plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605-613.
32. Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet. 1996; 348:1079-1082.
33. Endres M, Laufs U, Huang Z, et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A. 1998; 95:8880-8885.
34. Davenport J, Collins D, Babikian V, Brass LM, Rubins H, Robins S. Stroke Event and Risk Factors in the Veterans Affairs HDL Intervention Trial (VA-HIT). Stroke. 1999;30:256.
35. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360-381.
36. Furberg CD. Natural statins and stroke risk. Circulation. 1999;99:185-188.